Catumaxomab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Catumaxomab |
| DrugBank ID | DB06607 |
| Brand Names (EU) | Korjuny |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.64% |
Approved Indication (EMA)
Korjuny is indicated for the intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas, who are not eligible for further systemic anticancer therapy.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | severe nonproliferative diabetic retinopathy | 99.64% | DL |
| 2 | drug-induced osteoporosis | 99.58% | DL |
| 3 | diabetic retinopathy | 99.47% | DL |
| 4 | diabetic cataract | 98.45% | DL |
| 5 | kidney pelvis sarcomatoid transitional cell carcinoma | 98.29% | DL |
| 6 | prostatic urethra urothelial carcinoma | 98.27% | DL |
| 7 | infiltrating bladder urothelial carcinoma sarcomatoid variant | 98.25% | DL |
| 8 | renal pelvis papillary urothelial carcinoma | 98.18% | DL |
| 9 | transitional cell carcinoma | 98.07% | DL |
| 10 | HER2 positive breast carcinoma | 97.47% | DL |
| 11 | cortical cataract | 97.22% | DL |
| 12 | nuclear senile cataract | 97.22% | DL |
| 13 | senile cataract | 97.19% | DL |
| 14 | immature cataract | 96.90% | DL |
| 15 | diabetes mellitus type 2 associated cataract | 96.90% | DL |
| 16 | mature cataract | 96.90% | DL |
| 17 | tetanic cataract | 96.90% | DL |
| 18 | craniostenosis cataract | 96.90% | DL |
| 19 | psoriasis | 96.50% | DL |
| 20 | normal breast-like subtype of breast carcinoma | 96.45% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.